| Business Summary | | Xenova
Group
PLC
is
a
biopharmaceutical
group
based
in
the
United
Kingdom
focusing
on
the
discovery
and
development
of
novel
small-molecule
drugs,
primarily
for
the
treatment
of
cancer,
which
have
the
potential
to
be
administered
in
oral
and
intravenous
formulations.
Xenova
currently
operates
as
a
single
operating
unit,
Xenova
Limited.
Xenova
Limited
undertakes
the
discovery
and
development,
including
the
conduct
of
clinical
trials,
of
the
Company's
drug
candidates.
The
operating
unit
is
currently
undertaking
cancer
research
targeting
topoisomerases
I
and
II,
multi-drug
resistance,
PAI-1
and
telomerase.
It
has
two
drugs
in
clinical
trials:
XR9576,
designed
to
overcome
P-gp
mediated
multi-drug
resistance
in
common
cancer
types
as
an
addition
to
standard
chemotherapy,
and
XR5000,
a
drug
used
in
the
treatment
of
a
wide
range
of
cancers.
The
Company
also
has
early-stage
research
programs
targeting
MRP
in
cancer
and
in
asthma,
PAI-1
in
thrombosis
targets
and
the
inhibition
of
telomerase. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Xenova
is
a
biopharmaceutical
company
focused
on
the
discovery
and
development
of
novel
small-molecule
drugs,
primarily
for
the
treatment
of
cancer.
For
the
three
months
ended
3/31/01,
revenues
totalled
L0,
down
from
L78K.
Net
loss
before
U.S.
GAAP
rose
23%
to
L2.2
million.
Revenues
reflect
the
absence
of
software
license
sales.
Higher
loss
reflects
increased
research
and
development
expenditures,
and
the
inclusion
of
a
loss
on
the
sale
of
a
business. Recent Earnings Announcement For
the
3
months
ended
06/30/2001,
revenues
were
501;
after
tax
earnings
were
-4,308. (Preliminary; reported in thousands of British Pounds.) | More
from
Market Guide: Significant
Developments |
| Officers | | John
B.H. Jackson,
Chmn. David
A. Oxlade,
CEO Daniel
Abrams,
CFO/Secy. | More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|